Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biochimica et biophysica acta. Reviews on cancer

• Publication date

  2017-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbcan.2017.03.008PMID 28344099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• microRNA involvement in human cancer.

  2025cited by this paper
• Fulvestrant for hormone-sensitive metastatic breast cancer.

  2017cited by this paper
• Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.

  2017cited by this paper
• Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.

  2017cited by this paper
• Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy

  2017cited by this paper
• Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.

  2016cited by this paper
• High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

  2016cited by this paper
• Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

  2016cited by this paper
• Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.

  2016cited by this paper
• Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

  2016cited by this paper
• Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

  2016cited by this paper
• Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

  2016cited by this paper
• A phase II study of the PI3K inhibitor taselisib (GDC-0032) combined with fulvestrant (F) in patients (pts) with HER2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (BC).

  2016cited by this paper
• Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals

  2016cited by this paper
• Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:

  2016cited by this paper
• AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.

  2016cited by this paper
• Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.

  2016cited by this paper
• Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

  2016cited by this paper
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

  2016cited by this paper
• Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.

  2016cited by this paper
• RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

  2015cited by this paper
• Mechanisms of aromatase inhibitor resistance

  2015cited by this paper
• Roles for miRNAs in endocrine resistance in breast cancer.

  2015cited by this paper
• Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

  2015cited by this paper
• Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.

  2015cited by this paper
• Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.

  2015cited by this paper
• High expression of CDK6 protects breast cancer cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant treatment in estrogen receptor-positive metastatic breast cancer

  2015cited by this paper
• Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

  2015cited by this paper
• Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

  2014cited by this paper
• Extranuclear estrogen receptor's roles in physiology: lessons from mouse models.

  2014cited by this paper
• Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro

  2014cited by this paper
• Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

  2013cited by this paper
• Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial.

  2013cited by this paper
• miRNA dysregulation in breast cancer.

  2013cited by this paper
• Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

  2013cited by this paper
• Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex

  2013cited by this paper
• The interaction between ER and NFκB in resistance to endocrine therapy

  2012cited by this paper
• Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

  2012cited by this paper
• microRNA involvement in human cancer.

  2012cited by this paper
• Insulin-like growth factor receptor inhibitors: baby or the bathwater?

  2012cited by this paper
• AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies

  2012cited by this paper
• Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

  2012cited by this paper
• Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.

  2011cited by this paper
• Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer

  2011cited by this paper
• A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

  2011cited by this paper
• R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

  2011cited by this paper
• Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative?

  2011cited by this paper
• Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.

  2011cited by this paper
• Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer

  2011cited by this paper
• Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes

  2011cited by this paper
• Acquired endocrine resistance in breast cancer: implications for tumour metastasis.

  2011cited by this paper
• Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1

  2011cited by this paper
• Twist contributes to hormone resistance in breast cancer by down-regulating estrogen receptor alpha

  2011cited by this paper
• MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

  2011cited by this paper
• Antiestrogens and their therapeutic applications in breast cancer and other diseases.

  2011cited by this paper
• Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

  2011cited by this paper
• Insulin receptor and cancer.

  2011cited by this paper
• Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

  2011cited by this paper
• Mechanisms of endocrine resistance in breast cancer.

  2011cited by this paper
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

  2011cited by this paper
• MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer.

  2010cited by this paper
• Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

  2010cited by this paper
• Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors

  2010cited by this paper
• Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

  2010cited by this paper
• PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer

  2010cited by this paper
• Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

  2010cited by this paper
• Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically.

  2009cited by this paper
• Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

  2009cited by this paper
• Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

  2009cited by this paper
• Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

  2009cited by this paper
• Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant

  2009cited by this paper
• Targeting the phosphoinositide 3-kinase pathway in cancer

  2009cited by this paper
• The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival

  2009cited by this paper
• The insulin-like growth factor-I receptor as an oncogene

  2009cited by this paper
• Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

  2008cited by this paper
• Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

  2008cited by this paper
• Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

  2008cited by this paper
• Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer.

  2008cited by this paper
• Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.

  2008cited by this paper
• Crosstalk between IGF signaling and steroid hormone receptors in breast cancer.

  2007cited by this paper
• The role of microRNAs in cancer: no small matter.

  2007cited by this paper
• Fulvestrant (Faslodex) -- how to make a good drug better.

  2007cited by this paper
• Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer

  2007cited by this paper
• Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.

  2007cited by this paper
• Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions.

  2006cited by this paper
• Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant.

  2006cited by this paper
• Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

  2006cited by this paper
• Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.

  2006cited by this paper
• Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients

  2006cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• AKT activation predicts outcome in breast cancer patients treated with tamoxifen

  2005cited by this paper
• Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

  2005cited by this paper
• Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.

  2005cited by this paper
• Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.

  2005cited by this paper
• Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival

  2005cited by this paper
• Clinical development of fulvestrant ("Faslodex").

  2005cited by this paper
• Tissue transglutaminase-induced alterations in extracellular matrix inhibit tumor invasion

  2005cited by this paper

• Structural evolution progress of orally bioavailable selective estrogen receptor degraders.

  2025cites this paper
• Emerging pharmacology of targeted protein degraders.

  2025cites this paper
• OBHSA, a novel selective estrogen receptor degrader, overcomes tamoxifen resistance through cell cycle arrest and unfolded protein response-mediated apoptosis in breast cancer.

  2024cites this paper
• Identification of potential target genes of breast cancer in response to Chidamide treatment

  2022cites this paper
• Discovery of Highly Functionalized 5-hydroxy-2H-pyrrol-2-ones That Exhibit Antiestrogenic Effects in Breast and Endometrial Cancer Cells and Potentiate the Antitumoral Effect of Tamoxifen

  2022cites this paper
• Deregulated transcription factors and poor clinical outcomes in cancer patients.

  2022cites this paper
• Estrogen Receptors in Polycystic Ovary Syndrome

  2021cites this paper
• UNDERSTANDING THE ROLE OF ARGLU1 IN INTERFERON SIGNALING ACTIVATION IN BREAST CANCER

  2021cites this paper
• Resistance and Overcoming Resistance in Breast Cancer

  2020cites this paper
• Hormone Effects on Tumors

  2020cites this paper
• Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer

  2020cites this paper
• Breast Cancer and Ways to Diagnose the Risk Factors and Treat it During Pregnancy: A Narrative Review

  2020cites this paper
• Resistance and Overcoming Resistance in Breast Cancer

  2020cites this paper
• The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

  2019cites this paper
• PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

  2019cites this paper
• IL-1-conferred gene expression pattern in ERα+ BCa and AR+ PCa cells is intrinsic to ERα− BCa and AR− PCa cells and promotes cell survival

  2019cites this paper
• Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer

  2018cites this paper
• Basic Principles in Clinical Neuroendocrinology I: Receptor Mechanisms

  2018cites this paper
• Breast cancer metastatic dormancy and emergence, a role for adjuvant statin therapy

  2018cites this paper
• Molecular Mechanisms of Endocrine Resistance

  2018cites this paper
• Understanding how targeting zinc transporters prevents the development of aggressive cancer

  2018cites this paper
• Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.

  2017cites this paper